Literature DB >> 36127588

A Simple, Fast, and Reliable LC-MS/MS Method for the Measurement of Homovanillic Acid and Vanillylmandelic Acid in Urine Specimens.

Vrajesh Pandya1,2, Elizabeth L Frank3,4.   

Abstract

Homovanillic acid (HVA) and vanillylmandelic acid (VMA) are catecholamine metabolites used in the diagnostic workup of neuroendocrine tumors. Here we describe a simple dilute-and-shoot method for simultaneously quantitating HVA and VMA in human urine specimens. The method employs analyte separation on a reverse-phase liquid chromatography column followed by detection using electrospray ionization triple quadrupole mass spectrometry (ESI-MS/MS), wherein qualifier and quantifier ion transitions are monitored. This is a simple and fast analytical method with an injection-to-injection time of 4 min.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adrenal medulla; Homovanillic acid; Neuroblastoma; Pheochromocytoma; Vanillylmandelic acid

Mesh:

Substances:

Year:  2022        PMID: 36127588     DOI: 10.1007/978-1-0716-2565-1_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Liquid chromatography-tandem mass spectrometry method for the determination of vanillylmandelic acid in urine.

Authors:  Mark J Magera; Abby L Thompson; Dietrich Matern; Piero Rinaldo
Journal:  Clin Chem       Date:  2003-05       Impact factor: 8.327

Review 2.  Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines.

Authors:  Wilhelmina H A de Jong; Elisabeth G E de Vries; Ido P Kema
Journal:  Clin Biochem       Date:  2010-07-11       Impact factor: 3.281

3.  Simple dilute-and-shoot method for urinary vanillylmandelic acid and homovanillic acid by liquid chromatography tandem mass spectrometry.

Authors:  Zlatuse D Clark; Jeaneah M Cutler; Igor Y Pavlov; Frederick G Strathmann; Elizabeth L Frank
Journal:  Clin Chim Acta       Date:  2017-03-03       Impact factor: 3.786

Review 4.  Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.

Authors:  Ingrid Øra; Angelika Eggert
Journal:  Semin Cancer Biol       Date:  2011-07-20       Impact factor: 15.707

Review 5.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.